Navigation Links
Get personal to improve heart health
Date:2/23/2009

Scare tactics may not be necessary when trying to get patients at risk of heart disease to change their diet or behaviour, a new study has found. Instead, doctors and nurses should be aware of the stage of life their patients are at, and offer them very specific and targeted advice.

"The goal is to produce interventions which are sensitive to the lives and social position of those who find themselves at 'high risk' of coronary heart disease (CHD) in later-middle age, and which inspire change rather than inhibit it," say researchers, from Egenis, the ESRC Centre for Genomics in Society at the University of Exeter.

High-risk patients will often downgrade their risk in their own minds, yet could still be receptive to the behavioural change which is the purpose of CHD screening, explained Dr Hannah Farrimond, who studied the reaction of patients to being told they were at high risk. Boosting patients' sense of vulnerability does not help, and may even hinder, their efforts to change, the study found.

"Once patients have got over the shock of being at high risk of heart disease, they then tend to underplay their risk," says Dr Farrimond. "They compare themselves favourably with, say, others of the same age. In the past, researchers have thought we need to scare people into feeling at risk to make them change. This study suggests that even those who downplayed their risk still made changes, such as taking statins or exercising more. In other words, we don't need to scare people to get results. Clinical staff need to find other ways of encouraging patients to make the necessary lifestyle changes, such as offering personalised advice."

The findings of Dr Farrimond's paper 'Making sense of being at 'high risk' of coronary heart disease', are published in the current issue of the journal Psychology and Health.

Current NHS policy advocates screening in primary care to identify 'high risk' individuals for coronary heart d
'/>"/>

Contact: Claire Packman
c.h.packman@exeter.ac.uk
01-392-269-126
University of Exeter
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Research increases possibilities of personalizing treatment of infant osteosarcoma
2. Investing in personalized medicine will benefit Canada
3. Personal Health Technology Spending to Exceed $460 Million in the Disease Management Sector in 2013
4. Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care
5. Crossover Health Launches Personal Health Advisory Service
6. Final Economic Stimulus Bill Permits Americans Personal Health Information to Be Sold for Research and Public Health Purposes WITHOUT Patients Consent
7. MIT project uses personal digital assistants to track TB data
8. Leading UK Personal Trainer Challenges Standards of Service Within Fitness Industry to Get Results or Double Your Money Back Guarantee
9. New genomic test can personalize breast cancer treatment
10. User Centric Develops Guidelines for Personal Health Record (PHR) Applications Based on User Research
11. UCLA scientists develop crystal ball for personalized cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 2Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 3Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:U-M study: Work hassles hamper sleep 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 3Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 4Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 5Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 6Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 7Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 8Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 9Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 10Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 11Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 12Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 13Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 14Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 15Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 16Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 17Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 18Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 19Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 20Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 2Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 3
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7